BioSpace News Archive

Serac Healthcare Limited (“Serac Healthcare” or “the Company”) and the Nuffield Department of Women’s and Reproductive Health at the University of Oxford announce that preliminary data has been presented from the “Detecting Endometriosis expressed integrins using technetium-99m” (DETECT) imaging study, indicating that 99mTc-maraciclatide is capable of imaging superficial peritoneal endometriosis, the earliest stage of the disease.

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today reported its fourth quarter and full-year 2023 operating and financial results and reviewed recent business highlights.

Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommends CARVYKTI® (ciltacabtagene autoleucel, cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) and who are refractory to lenalidomide.

Rani Therapeutics Holdings, Inc. today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2023 and provide a business update on Wednesday, March 20 after the close of trading.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 11, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 8,904 shares of common stock and 5,461 restricted stock units (“RSUs”) to three new employees under Acadia’s 2023 Inducement Plan.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

The U.S. plasmid DNA contract manufacturing market size is expected to surpass around USD 849.23 million by 2033 and growing at a CAGR of 19.25% from 2024 to 2033.

Navigate BioPharma Services, Inc. in Collaboration with Partners Validate Analytical Assay for Acute Myeloid Leukemia Measurable Residual Disease (AML-MRD) Assessment.

Avenue Therapeutics, Inc. today announced that by decision dated March 11, 2024, the Nasdaq Hearings Panel granted the Company’s request for an extension to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market.

Journey Medical Corporation today announced the Company will release its year end 2023 financial results after the U.S. financial markets close on Thursday, March 21, 2024.